Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32666863 | 1.00 | PTK2 (0.59) | PTK2DEGS1CYP1A2GAAKMT2A | |
| SCHEMBL14824272 | 0.88 | PTK2 (0.57) | PTK2DEGS1CYP1A2GAAKMT2A | |
| SCHEMBL23270830 | 0.86 | DEGS1 (0.55) | PTK2DEGS1RAB9AMAPTL3MBTL1 | |
| SCHEMBL19728673 | 0.84 | DEGS1 (0.54) | DEGS1RAB9AMAPTL3MBTL1KDM4E | |
| SCHEMBL23139476 | 0.83 | DEGS1 (0.52) | PTK2DEGS1RAB9AMAPTL3MBTL1 | |
| SCHEMBL2054674 | 0.83 | DEGS1 (0.52) | PTK2DEGS1KMT2ARAB9AMAPT | |
| SCHEMBL8252662 | 0.82 | DEGS1 (0.49) | DEGS1 | |
| SCHEMBL19107529 | 0.82 | DEGS1 (0.48) | PTK2DEGS1CYP1A2GAAKMT2A | |
| SCHEMBL29376899 | 0.81 | DEGS1 (0.51) | DEGS1RAB9AMAPTL3MBTL1NPC1 | |
| SCHEMBL9888659 | 0.81 | DEGS1 (0.51) | PTK2DEGS1CYP1A2GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-20230060011-A1 | ANTIBACTERIAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2023-02-23 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| WO-2012052745-A1 | COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110237582-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-09-29 | — | — | US | disclosed |
| US-20100240657-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010034838-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009003998-A2 | ANTIPROLIFERATIVE COMPOUNDS BASED ON 5-MEMBERED HETEROCYCLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | PTK2 185/4885DEGS1 2793/4885CYP1A2 3870/4885 |
| US-20230060011-A1 | ANTIBACTERIAL COMPOUNDS | GAA, MGAM, NQO1 | PTK2 4029/4885DEGS1 3111/4885CYP1A2 375/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | PTK2 2104/4885DEGS1 3849/4885CYP1A2 928/4885 |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | PTK2 908/4885DEGS1 831/4885CYP1A2 174/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | PTK2 3843/4885DEGS1 4366/4885CYP1A2 4867/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | PTK2 1737/4885DEGS1 3302/4885CYP1A2 4369/4885 |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | PTK2 1981/4885DEGS1 1232/4885CYP1A2 386/4885 |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PTK2 205/4885DEGS1 973/4885CYP1A2 2991/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | PTK2 1688/4885DEGS1 3870/4885CYP1A2 380/4885 |
| US-20100240657-A1 | CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | PTK2 1701/4885DEGS1 832/4885CYP1A2 92/4885 |
| US-20110237582-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | PTK2 2104/4885DEGS1 3849/4885CYP1A2 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.